tRNAs possess a high content of modified nucleosides, which display an incredible structural variety. These modified nucleosides are conserved in their sequence and have important roles in tRNA functions. Most often, hypermodified nucleosides are found in the wobble position of tRNAs, which play a direct role in maintaining translational efficiency and fidelity, codon recognition, etc. One of such hypermodified base is queuine, which is a base analogue of guanine, found in the first anticodon position of specific tRNAs (tyrosine, histidine, aspartate and asparagine tRNAs). These tRNAs of the 'Q-family' originally contain guanine in the first position of anticodon, which is post-transcriptionally modified with queuine by an irreversible insertion during maturation. Queuine is ubiquitously present throughout the living system from prokaryotes to eukaryotes, including plants. Prokaryotes can synthesize queuine de novo by a complex biosynthetic pathway, whereas eukaryotes are unable to synthesize either the precursor or queuine. They utilize salvage system and acquire queuine as a nutrient factor from their diet or from intestinal microflora. The tRNAs of the Q-family are completely modified in terminally differentiated somatic cells. However, hypomodification of Q-tRNA (queuosine-modified tRNA) is closely associated with cell proliferation and malignancy. The precise mechanisms of queuine-and Q-tRNA-mediated action are still a mystery. Direct or indirect evidence suggests that queuine or Q-tRNA participates in many cellular functions, such as inhibition of cell proliferation, control of aerobic and anaerobic metabolism, bacterial virulence, etc. The role of Q-tRNA modification in cellular machinery and the signalling pathways involved therein is the focus of this review.
INTRODUCTION
The presence of modified nucleosides is a distinctive structural feature of tRNA which leads to structural variety [1] . An important function of the modified nucleosides is in structural formation and stabilization of functional RNAs [2] . The degree of modification varies with the source of tRNA and appears to increase in amount with the evolutionary development of the organism. Maximum number of modified bases are found in human tRNA, whereas they appear much less in bacterial tRNA [3] . Currently, the structure of more than 93 modified nucleosides is well known [4] . The role of all the modified nucleosides is still not clear, although their importance is slowly emerging.
Modified bases in tRNA influence or modulate its activity at various levels, such as the rate of initiation of protein synthesis [5, 6] , in vitro peptide elongation [7, 8] , kinetics of aminoacyl-all the phylogenic domains, namely archaea, bacteria and eukaryotes [25] . Some are even present at comparative position in tRNA from all three phylogenic domains, for example, 13, Cm32, m 1 G37, t 6 A37, 38, 39, 55 and m 1 A58 [26] . The distribution of modified nucleosides in tRNA in the different phylogenic domains supports the concept that there are three different lines of descent from a common ancestor [27] . Some modified nucleosides are specific to archaea, bacteria or eukaryotes, suggesting that these modified nucleosides have evolved after the three phylogenic domains divided [28, 29] .
The most characteristic feature of tRNAs is presence of hypermodified nucleosides in the anticodon loop and stem (positions [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . They contribute to the decoding properties (efficiency and accuracy) of tRNA molecules during translation [8, 30, 31] . A majority of hypermodified nucleosides, such as queuosine, 2-Omethylguanosine and inosine, are present at position 34 of anticodon loop, whereas others, such as m 6 t 6 A, ms 2 I 6 A and Y base, are present at position 37 (3 adjacent to the anticodon). Other modified nucleosides, such as , Gm, Um, s 2 C, m 3 C and m 5 C, are present elsewhere in the anticodon branch. They are needed to modulate the flexibility and preferential 3 stacking conformation adopted by the anticodon loop when it binds to complementary codon [32, 33] . The presence of modified nucleosides in the anticodon loop is important for modulation of codon-anticodon interactions and helps to maintain the correct reading frame during translation [34] . They may not be essential for viability, but play an important role in fine-tuning of tRNA activities [35] .
The two most important hypermodified nucleosides that are known to occur in tRNA are queuosine and archaeosine, both of which are characterized by a 7-deazaguanosine core structure. They are rigorously segregated with respect to phyla and location in tRNAs. Queuosine is ubiquitously present throughout living systems, where it occurs specifically at a wobble position in specific tRNAs; however, archaeosine is found exclusively in archaea, where it is found in majority of known archaeal tRNAs at position 15 of the D-loop (dihydrouridine loop), which exhibits many important developmental and cellular functions in the cells [36] .
QUEUINE
In 1968, a previously undescribed nucleic acid base was identified in Escherichia coli tRNA Tyr hydrolysate that could not be matched with the established standards. It was given the designation as 'Q'. The base form of Q was named queuine and nucleoside queuosine. Queuosine was first discovered in the first position of anticodon loop (position 34) of E. coli tRNA Tyr . Later, it was found that queuosine is also present in the same position in E. coli tRNA His , tRNA Asn and tRNA Asp [37] . The structure of queuosine was determined by gas chromatography/MS and elucidated by X-ray crystallography [38, 39] . Queuosine was identified as a hypermodified guanosine analogue. The N-7 position of purine ring is substituted with a C-7 in queuosine, which is the site of attachment for aminomethyl ether to a dihydroxycyclopentenediol ring (Figure 1) . The basic queuosine molecule is defined as 7-(3,4-trans-4,5-cis-dihydroxy-1-cyclopenten-3-ylaminomethyl)-7-deazaguanosine [40, 41] .
QUEUOSINE MODIFICATION OF tRNA: TGTase (tRNA-GUANINE TRANSGLYCOSYLASE)
tRNA is post-transcriptionally modified to Q-tRNA with the help of key enzyme TGTase (EC 2.4.2.29), which catalyses the baseexchange reaction in which guanine is replaced with queuine or its precursor at the anticodon position 34 of cognate tRNAs (histidine, asparagine, aspartate and tyrosine tRNAs) [42, 43] . This replacement of genetically encoded base guanine with a modified base queuine is found across the three domains of life, including archaea, eubacteria and eukaryotes [44] [45] [46] . Queuosine modification of tRNA is evolutionarily conserved, but the process of modification is significantly different in prokaryotes and eukaryotes [36, 44, [47] [48] [49] . In prokaryotes, queuosine modification of tRNA is achieved by multi-step de novo biosynthesis, whereas the modification of tRNA is a single step of enzymatic reaction in the case of eukaryotes. Its phylogenic segregation is correlated with unique modified base substrate specificity and disparate tRNA recognition element [47, 50, 51] . The prokaryotic TGTase catalyses a post-transcriptional trans-glycosylation reaction during incorporation of the modified base queuine into specific tRNAs [52, 53] . It reversibly incorporates the partially modified base preQ 1 (7-aminomethyl-7-deazaguanine) as a primary substrate into tRNA by a base-exchange reaction [54] . This baseexchange reaction does not require cleavage of phosphodiester backbone of the polynucleotide, nor does it require energy input, for example, ATP hydrolysis [43, 55] . On the other hand, the eukaryotic TGTase utilizes the completely modified base queuine as a substrate and irreversibly incorporates it at position 34 of specific tRNAs by a base-exchange reaction [14] . In contrast, archaeal TGTase incorporates archaeosine at position 15 of the D-loop of many tRNAs to maintain their structure [51, 55] . From sequence databases, all three classes of TGTase (eubacteria, eukaryotes and archaea) share a high degree of sequence similarity (approx. 40 %) in domain-specific structural properties [47] . The prokaryotic TGTase has been characterized in a number of studies. It is a monomeric protein of approx. 43-46 kDa [52, 56, 57] . A crystallographic study of E. coli TGTase suggests that it is a zinc metalloenzyme. Structurally, TGTase is TIM (triose-phosphate isomerase)-like (β/α) 8 barrel protein (Figure 2) . Eukaryotic TGTase, purified from bovine liver [58] , rat liver [59] and rabbit erythrocytes [60] , was shown to be a heterodimer complex of 100-104 kDa protein, comprising a putative 60-66 kDa regulatory subunit and 34-45 kDa catalytic subunit. However, catalytic subunits of TGTase are structurally well conserved [44] . Recently, the eukaryotic TGTase was reported to be a heterotrimeric protein which weakly interacts with the mitochondrial outer membrane [61] .
Queuosine modification of tRNA in the prokaryotic system
The mechanism of queuosine modification of tRNA in prokaryotes has been identified in E. coli, Salmonella typhimurium and Zymomonas mobilis [42, 54, 57] . Reader et al. [62] have reported that four genes (queC, queD, queE and queF) are essential for synthesis of the intermediates preQ 0 (7-cyano-7-deazaguanine) or preQ 1 in bacteria, which are subsequently transferred into the appropriate tRNA in a guanine-exchange reaction that catalysed by TGTase. Queuosine is formed by a multi-step intracellular pathway, which involves de novo enzymatic synthesis on an intact tRNA. The first step of queuosine synthesis involves the conversion of a GTP molecule into a preQ 1 or a preQ 0 derivative of the guanine base [50, 64] . This step is performed by GTPcyclohydrolase-like enzyme, which involves removal of both the N-7 and C-8 atoms of the nucleotide base and incorporation of either an aminopropyl or cyanopropyl group respectively to re-form the ring [62, 65] . The preQ 1 base is further inserted into the first anticodon position of Q-family tRNAs by a base-to-base exchange reaction. This reaction is catalysed by the prokaryotic TGTase enzyme [52, 66] . The TGTase enzyme appears to utilize guanine, preQ 0 or preQ 1 as a substrate for incorporation into tRNAs with low K m values in the nanomolar range [67] . The incorporation reaction for guanine and perQ 0 are completely reversible; however, the reaction involving preQ 1 is irreversible. The irreversibility of the reaction and relative abundance of the incorporation of preQ 1 is due to the low K m value, suggesting that this compound serves as the natural substrate for this enzyme [42] . The incorporated preQ 1 is further modified by SAM:TRTase (S-adenosylmethionine:tRNA ribosyltransferase) into epoxyQ (2,3-epoxy-4,5-dihydroxycyclopentyl-7-aminomethyl-7-deazaguanosine). S-Adenosylmethionine plays an important role as a ribose donor for formation of queuosine which usually functions as a methionyl or methyl group donor. It serves as a substrate for SAM:TRTase in the attachment of the cyclic ring to the end of the 7-aminomethyl side chain of the incorporated 7-deazaguanosine residue and produces modified epoxyQ [63, [68] [69] [70] . Finally, epoxyQ is converted into queuosine by an unknown mechanism which requires coenzyme B 12 (Figure 3 ). The formation of queuosine appears to be regulated by the availability of the metabolic substrates GTP, Sadenosylmethionine and vitamin B 12 , as well as the co-ordinated expression of the modification enzymes from the queuine operon [41, [71] [72] [73] . After synthesis of fully formed queuosine, the modified tRNA participates in normal cellular functions until it is degraded by natural tRNA turnover. The resulting queuosine nucleoside, nucleotide and queuine base are not salvaged by prokaryotes after degradation of tRNA. Queuine and queuosine are lost to the surrounding environment as metabolic waste products [55, 74, 75] .
Queuosine modification of tRNA in the eukaryotic system
Eukaryotes are unable to synthesize queuine itself. They obtain it from diet or intestinal microflora [62, 76] . Queuine is directly incorporated in place of guanine at first position of anticodon loop of specific tRNAs of the Q-family, i.e. His, Asn, Asp and Tyr tRNAs, by a single-step enzymatic reaction catalysed by eukaryotic TGTase [58, 77, 78] (Figures 4 and 5) .
Germ-free mice fed with a queuine-free diet are found to be deficient in queuosine modification of tRNA, whereas exogenous administration of queuine improves queuosine modification level in tRNA [79, 80] . The nematode Caenorhabditis elegans, fed with queuine-deficient E. coli, showed an absence of queuine modification of tRNA [81] . The queuosine modification system in mammalian cells may depend on three steps: uptake of queuine base into the cells by a queuine-specific membrane transport system, incorporation of queuine into the first position of the anticodon loop of tRNA by an enzymatic reaction catalysed by TGTase and salvage of queuine from queuosine 5 -monophosphate, resulting from tRNA degradation. All these three steps are potential points for deficiency in cellular queuosine modification level of tRNA [82, 83] . The mammalian queuosine modification system maintains a specific cellular membrane uptake mechanism to move queuine from extracellular space into the cytosol and incorporates it into intact tRNA post-transcriptionally [84] . The cellular uptake of queuine and its incorporation is modulated by phosphorylation of the modifying enzyme TGTase [83] . Activation of protein kinase C by a phorbol ester elevates both the rate of transport and incorporation [85] . Protein kinase C activates TGTase activity, as well as the cellular uptake mechanism for queuine, and supports complete modification of tRNA with queuine [59, 84] . Morris et al. [83] have reported that protein kinase C and protein phosphatase modulate the rate of queuine uptake into the cell and subsequent incorporation into the anticodon of tRNAs; therefore aberrant kinase activity and/or phosphatase activity may also affect queuosine modification of tRNAs. Eukaryotic cells have the ability to salvage this base from tRNA turnover products to maintain the cytosolic level of queuine under conditions of dietary queuine deprivation [74, 75] .
OCCURRENCE OF Q-tRNA
In biological systems, the queuine base is known to exist in four forms: free queuosine base, free nucleoside, free nucleotide and nucleoside incorporated into tRNA (Q-tRNA). Under normal physiological conditions, tRNAs of the Q-family are completely modified in terminally differentiated somatic cells. However, queuosine modification of tRNA is often incomplete in undifferentiated rapidly growing cells, embryonic tissues and regenerating hepatocytes [86, 87] . Similarly queuosine deficiency in tRNAs is observed in human placenta [88] . Alteration in the level of queuosine in tRNA has been observed during differentiation and development in Dictyostelium discoideum [89, 90] , Drosophila melanogaster [91] and during the development and aging of rats [92] . Variations in the modification level of tRNAs occur in eukaryotes from organ to organ [93] .
BIOLOGICAL FUNCTION OF QUEUINE
Owing to the presence of queuine at the wobble position of several tRNAs, studies have investigated its role in codon-anticodon pairing. Meier et al. [94] have reported that tRNA His (G34) clearly prefers the histidine codon CAC to the codon CAU, whereas tRNA His (Q34) has little preference for the codon CAU. Furthermore, queuosine-modified tRNAs have been shown to suppress stop codons as tRNA Tyr (G34) allows stop codon readthrough, whereas tRNA Tyr (Q34) prevents it [95] [96] [97] [98] [99] . However, there is no direct evidence providing a link between hypomodification of tRNA and frameshifting. Queuosine modification of tRNA has been correlated with low-level translation of a bacterial (Shigella) virulence protein mRNA [100, 101] .
PHYSIOLOGICAL ROLE OF QUEUINE
The precise physiological role of queuine has not been established to date. When a queuine-free diet was fed to germ-free mice, the mice did not show any pathological symptoms in a stressless environment, suggesting that the role of queuine may be to protect organisms against stress [102, 103] . A correlation between queuine abundance and stress tolerance has been reported by Gaur et al. [73] .
Queuine plays an important role in tyrosine biosynthesis in mammals [104] . In absence of queuine, tyrosine becomes an essential amino acid for normal development of mouse. Similarly
TGTase, the enzyme responsible for modification of Q-tRNA, has been recognized as one of the key enzyme in the regulation of bacterial virulence in Shigella flexneri. A strong reduction in virulence is achieved by reduction or loss of TGTase activity [105, 106] , suggesting it as a putative target for drug design [107, 108] .
ROLE OF QUEUINE IN THE CELLULAR ANTIOXIDANT DEFENCE SYSTEM
Organisms have developed an intricately regulated antioxidant defence system to protect against toxic effects of ROS and to modulate the physiological effects of ROS. Endogenous antioxidants are enzymatic and non-enzymatic in action. The major antioxidant enzymes are catalase, superoxide dismutase and glutathione peroxidase, and non-enzymatic antioxidants are thiol, glutathione, ascorbate, urate etc., which protect against oxidative stress by preventing the uncontrolled formation of free radicals and activated oxygen species. De-regulation of the balance between production of ROS by normal cellular processes and their removal by antioxidant enzymes in favour of the oxidants causes oxidative stress [109] , which leads to various pathological conditions, including metabolic dysfunction and cardiovascular diseases, such as atherosclerosis, pulmonary fibrosis and neurodegenerative diseases, as well as malignancy.
Queuine promotes the activity of the antioxidant enzymes, such as catalase, superoxide dismutase, glutathione reductase, glutathione transferase, etc., suggesting that queuine improves the antioxidant defence system [110] . Thus queuine may be regarded as an antioxidant compound to protect the antioxidant defence system.
REGULATION OF GLYCOLYTIC METABOLISM BY QUEUINE
The free-base queuine or Q-tRNAs play an essential role in adaptive regulation of glycolytic metabolism, depending upon anaerobic or aerobic conditions [17] . Proliferating and cancer cells maintain a high rate of glycolysis, even under aerobic conditions, leading to high rate of lactate formation [111] [112] [113] . Alterations in expression of different LDH (lactate dehydrogenase) isoenzymes are associated with clinical diseases, such as cancer [114] [115] [116] [117] , myocardial infarction [118] and liver disorders [119] . Elevated level of LDH-A is associated with proliferation and a variety of malignancies [120] [121] [122] [123] . The major anoxic stress protein LDH k/6 is highly expressed in various human cancer and transformed cells [124, 125] . LDH k/6 activity is suppressed by the modified base queuine [126] . Specific changes in LDH level and isoenzyme pattern by queuine are observed in D. discoidium [127] and in cancerous mice [128, 129] to down-regulate anaerobic metabolism. Queuine protects HeLa cells from hypoxic stress and improves metabolic adaptation [18, 130] .
EFFECT OF QUEUINE ON CELL PROLIFERATION
Queuine may act as a positive or a negative modulator of cell proliferation, depending on the aerobic or glycolytic state of cells and on the availability of free queuine base. It is not directly related to the presence or absence of Q-tRNA [21] . Queuine inhibits cell proliferation of a number of cell lines, including Colo-DM320, PC-12, C3H, U87, HepG2, ascite tumour, transformed NIH 3T3 and EGF (epidermal growth factor)-supported proliferation of HeLa cells [131, 132] . The inhibition is co-related with an increase in apoptosis. However, proliferation is stimulated in the case of HeLa S3, A-431 and HL-60 cells [18] . Queuine induces cell differentiation in cancerous cells [133] .
QUEUOSINE DEFICIENCY OF tRNA AND CANCER
The lack of queuine in the first position of anticodons is found in tRNAs of Q-family from various tumour cells [54, 75, 134] . tRNAs, isolated from neoplastic tissues and transformed cells, are hypomodified with queuosine to various degrees. The level of queuosine deficiency of tRNA is high in lung cancer as compared with normal tissue [135] . The degree of hypomodification is related to the severity of malignancy in human lymphoma, leukaemia, lung cancer, ovarian carcinoma and brain tumour [74] . A correlation between the level of queuosine modification of tRNA in cancerous tissues of human and grade of malignancy has been reported by several laboratories [23, [135] [136] [137] , which are of value for the prognosis of various cancers. The level of quenine-lacking tRNA is substantially greater in high-grade malignant lymphomas and immunoblastic lymphomas compared with low-grade malignancies [23] . The amount of queuosine-deficient tRNA is strongly correlated to the histopathological grade of malignancy. There is a positive correlation between the level of queuosine modification of tRNA and survival of the patients [23] . Queuosine deficiency of tRNA increases in metastastic ovarian malignant tumours compared with primary ovarian malignancies [137] . The level of queuine deficiency in tRNA is found to be significantly higher in astrocytomas (malignant brain tumours) than in meningiomas (benign brain tumours) [136] . tRNA isolated from liver of cancerous mouse is hypomodified with respect to queuosine, as compared with normal mouse liver [138] . Queuine administration leads to Q-tRNA modification, along with a decrease in the proliferation capacity of tissues [132] .
Okada et al. [93] have reported that the presence of hypomodified tRNA in transformed cells is not simply due to their high growth rate, but closely related to state of differentiation. tRNA isolated from mitochondria of Morris hepatoma (5123D) has been found to lack queuosine, suggesting that a queuosine defect may develop at an early stage of carcinogenesis and may be directly associated with abnormalities of mitochondria [139] .
Queuosine hypomodification of tRNA in cancer might be due to one or a number of different causative factors, such as a decrease in incorporation of modified base queuine due to inactivation of the enzyme or loss of queuine uptake regulated by protein kinase C, by aberrant kinase or phosphatase activity [140] or loss of the ability to salvage queuine from the tRNA turnover process [74, 75] . An elevated level of tRNA turnover and urinary excretion of modified nucleosides is characteristic feature of malignancies [141, 142] . It may be possible that queuine is not salvaged completely and excreted with urine due to the high turnover rate of tRNA or to inactivation of TGTase. DNA methylation is known to be high in cancer cells. The presence of methylated purines in cancer cells inhibits TGTase activity and queuosine modification of tRNAs [143] . These factors ultimately target TGTase and make it inactive. Hypomodification of tRNA in cancerous tissues is correlated with the loss of TGTase activity [140] .
QUEUINE AND CELL SIGNALLING
The most important extracellular signalling molecules regulating cell proliferation are growth factors, which provide increased survival response to cancer cells. The binding of ligands to receptors results in autophosphorylation of multiple tyrosine residues in the cytoplasmic domains of the growth factor receptors, which, in turn, activates intracellular signal transduction, enhances transcription of growth-related genes and promotes cell growth [144] . An abnormal level of phosphorylation of membrane or nuclear proteins is associated with malignancy [145] . An increased level of EGFR (EGF receptor) mRNA and protein has also been found in a variety of human cancers [146, 147] . Queuine modulates the proliferation of HeLa cells in presence of EGF and PDGF (platelet-derived growth factor), acting as an antagonist to EGF, but as a synergist with PDGF [148] . Queuine has been shown to modulate mitotic signalling initiated by EGFR in vitro by tyrosine phosphorylation of specific membrane-associated proteins [130, 149, 150] . The addition of queuine to queuine-starved cells or in an in vitro system affects protein synthesis and protein phosphorylation [151, 152] . Thus queuine is proposed to have important role in mitotic signalling.
EFFECT OF QUEUINE ON PROTO-ONCOGENES
The precise regulation between cell proliferation and cell death in multicellular organism is critical for tissue homoeostasis. Protooncogenes regulate normal cell proliferation and differentiation, but their mutant forms contribute in neoplastic transformation. The cellular proto-oncogenes induced in response to growth factors or mitogens play an important role in regulation of the cell cycle and mitogenic responses [153] [154] [155] . The c-fos protooncogene is an immediate early response gene that is rapidly and transiently induced in a wide range of cell types in response to a variety of extracellular stimuli, including serum, growth factors and cytokines [156, 157] . Expression of c-fos is also regulated post-transcriptionally. It is short-lived and degraded by ubiquitinmediated proteolysis [158] . Overexpression of c-fos is associated with transformation of cells and tumorigenesis [159, 160] . Similarly, c-myc targets a wide range of genes that co-ordinate cell-cycle progression and cell growth, which sensitize the cell to apoptotic stimuli [161, 162] . Elevated expression of c-myc is found in various human cancers, including lymphoma [163, 164] , lung cancer [165] , breast cancer [166, 167] , colon cancer [168] and hepatocellular carcinoma [169] [170] [171] . c-Myc is a transcriptional regulator and key component in controlling cell growth [172, 173] . An increase in activity of the LDH-A isoenzyme is associated with activation of c-myc proto-oncogenes [174, 175] . The LDH-A promoter is reported to contain two consensus Myc/Maxbinding sites or E-boxes CACGTG (located at −78 to −83 and −175 to −180 from the transcriptional start site) that are conserved in both mouse and human. It has been suggested that c-Myc may be able to regulate transcription of LDH-A, leading to enhanced glycolytic metabolism [176, 177] .
Queuine-dependent down-regulation of c-myc and c-fos expression has been observed in HeLa cells [151] , as well as in cancerous mouse liver [130] . On the other hand, the proto-oncogene bcl-2 and its family are involved in the regulation of cell death and survival, without affecting cell proliferation [178] . The product of the bcl-2 family, acting in the apoptotic pathway has both pro-and anti-apoptotic properties. The regulation of apoptosis is mediated by a dynamic balance between the cell death repressor proteins Bcl-2 and Bcl-x L and death-activator proteins, such as Bax and Bcl-x s . Up-regulation of bax or down-regulation of bcl-2 facilitate apoptosis [179] . Queuine is possibly involved in the regulation of apoptosis by decreasing bcl-2 gene expression [132] . The available evidence suggest that queuine suppresses malignancy by down-regulation of proto-oncogenes, by up-regulation of apoptosis, by inhibiting anaerobic metabolism of tumours and by checking oxidative stress. Queuine also helps in stress tolerance. The available knowledge regarding the physiological role of queuine provides a basis to propose queuine as an anticarcinogenic agent.
The overview of the impact of queuine base and/ or Q-tRNA on cellular and physiological functions that are known to date exposes the unknown steps followed by them in signalling pathways to execute the overall response ( Figure 6 ).
FUTURE PROSPECTS
Insufficiently defined signalling pathways adopted by queuine and/or Q-tRNA pose a challenge for the workers in this field. Further research is needed to ascertain whether the biological actions are all executed by Q-tRNA, or both by the queuine base and Q-tRNA. Similarly, the basic role of queuosine modification of tRNA in the modulation of codon-anticodon recognition is poorly understood. We are totally ignorant regarding the transcriptional control over the qrt gene or the inducible queuine salvage gene. In-depth analysis of the impact of queuine or Q-tRNA on biological functions and the molecular mechanism involved therein is premature and needs to be addressed thoroughly.
CONCLUSIONS
The presence of queuine or Q-tRNA has been correlated with a number of physiological functions. However, its exact role is still not clear. Queuine base or Q-tRNA is probably required for better survival of organisms under stress conditions, in addition to their normal growth. Queuine decreases oxidative stress by modulating the antioxidant defence system, as well as anaerobic metabolism. The down-regulation of proto-oncogenes and tyrosine phosphorylation of membrane proteins by queuine, along with its antioxidant activities, suggest that queuine is a putative anticarcinogenic agent. However, the exact contribution of queuine and Q-tRNA in the physiological actions is not known. Although several laboratories have generated data concerning the potential of queuosine-modified tRNA to modulate translational efficiency, strong experimental evidence for a unified theme of its molecular function is still lacking. Therefore serious efforts are needed to explore the holistic action of queuine or Q-tRNA in the cellular machinery that contributes towards normal physiology.
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